Immunocore Revenue and Competitors
Estimated Revenue & Valuation
- Immunocore's estimated annual revenue is currently $27.4M per year.
- Immunocore's estimated revenue per employee is $55,141
- Immunocore's total funding is $808.8M.
- Immunocore's current valuation is $1B. (January 2022)
Employee Data
- Immunocore has 496 Employees.
- Immunocore grew their employee count by 21% last year.
Immunocore's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CTO - Head Pipeline & Platform Research and UK site Head | Reveal Email/Phone |
2 | Chief Staff to the Chief Medical Officer | Reveal Email/Phone |
3 | CTO - Head Pipeline & Platform Research | Reveal Email/Phone |
4 | CEO | Reveal Email/Phone |
5 | VP, Clinical Development | Reveal Email/Phone |
6 | VP Finance Operations, FP&A and Procurement | Reveal Email/Phone |
7 | Head Pipeline Biology | Reveal Email/Phone |
8 | VP, Business Development | Reveal Email/Phone |
9 | Head Clinical Supply Chain | Reveal Email/Phone |
10 | Head Medical Affairs Europe | Reveal Email/Phone |
Immunocore Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $10.1M | 65 | 5% | N/A | N/A |
#10 | $16.1M | 104 | 9% | N/A | N/A |
What Is Immunocore?
Immunocore is a leading T cell receptor (TCR) biotechnology company working to create first-in-class biological therapies to address unmet patient needs in oncology as well as infectious and autoimmune diseases. Immunocore has a pipeline of proprietary and partnered programmes in development. Collaboration partners include Genentech, GlaxoSmithKline, AstraZeneca, Lilly, and the Bill and Melinda Gates Foundation. Immunocore is headquartered in Oxfordshire, UK, with offices in Conshohocken, PA and Rockville, MD, US. The Company is privately held by a broad international investor base. See our community guidelines: http://bit.ly/2kFA8hr
keywords:N/A
$808.8M
Total Funding
496
Number of Employees
$27.4M
Revenue (est)
21%
Employee Growth %
$1B
Valuation
N/A
Accelerator
Immunocore News
Immunocore (NASDAQ:IMCR) Downgraded by Zacks Investment Research to Hold. Posted by admin on Apr 13th, 2022. Share on Twitter Share on Facebook Share on...
Immunocore Holdings PLC - ADR (IMCR) stock has gained 9.19% over the last 12 months, and the average rating from Wall Street analysts is a...
ROCKVILLE, Md., US, 4 April 2022) Immunocore Holdings plc (Nasdaq: ... on the results of Immunocore's Phase 3 IMCgp100-202 clinical trial,...
Immunocore Holdings plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, today announced the closing ...
Immunocore Holdings plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, today announced the closing ...
Other Companies in Abingdon
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $126.7M | 563 | N/A | N/A |
#2 | $329.9M | 725 | 13% | N/A |
#3 | $218M | 771 | 8% | N/A |
#4 | $220.3M | 779 | -3% | N/A |
#5 | $187.6M | 822 | -19% | N/A |